OMER
What one share of Omeros holds
Pharmaceutical Preparations
Omeros Corporation (“Omeros,” the “Company” or “we”) is an innovative, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders.
Omeros’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $1.77 |
|---|---|
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.98 |
| Cash and investments | $0.03 |
| Debt | $1.02 |
| Book value | −$0.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2009 | $0.20 | −$2.92 | $0.04 | −$2.67 | — | $5.97 |
| 2010 | $0.10 | −$1.37 | $0.04 | −$0.71 | — | $0.93 |
| 2011 | $0.20 | −$1.29 | $0.06 | −$1.21 | — | −$0.25 |
| 2012 | $0.25 | −$1.59 | $0.03 | −$1.46 | — | −$0.25 |
| 2013 | $0.06 | −$1.39 | $0.01 | −$1.05 | — | −$0.61 |
| 2014 | $0.02 | −$2.22 | $0.00 | −$1.75 | — | −$1.25 |
| 2015 | $0.36 | −$2.00 | $0.01 | −$1.74 | — | −$0.69 |
| 2016 | $1.03 | −$1.65 | $0.00 | −$1.28 | — | −$0.85 |
| 2017 | $1.42 | −$1.17 | $0.01 | −$0.80 | — | −$0.06 |
| 2018 | $0.61 | −$2.61 | $0.01 | −$2.15 | — | −$2.04 |
| 2019 | $2.26 | −$1.71 | $0.01 | −$1.22 | — | −$2.01 |
| 2020 | $1.29 | −$2.41 | $0.00 | −$1.76 | — | −$1.96 |
| 2021 | — | $3.12 | $0.00 | −$1.76 | — | $0.38 |
| 2022 | — | $0.76 | $0.00 | −$1.38 | — | $1.36 |
| 2023 | — | −$1.88 | $0.01 | $1.18 | — | −$0.41 |
| 2024 | — | −$2.70 | $0.00 | −$2.56 | — | −$3.15 |
| 2025 | — | −$0.05 | $0.00 | −$1.83 | — | −$1.69 |